Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRST-308: tinengotinib versus physician's choice in FGFR2-altered relapsed/refractory cholangiocarcinoma
2023-505660-11-00Phase 3Authorised
- Sponsor
- TransThera Biosciences
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of tinengotinib in cholangiocarcinoma (CCA) (2 arms), sponsored by TransThera Biosciences. Primary endpoints: Incidence, duration, and severity of adverse events and Progression-free survival by blinded independent central review. Planned start Feb 2024; status: authorised.
02
Drugs
tinengotinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2023-505660-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505660-11-00.